| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genetic Testing | 93 | 2024 | 3591 | 7.550 |
Why?
|
| Genomics | 71 | 2024 | 5923 | 4.930 |
Why?
|
| Alzheimer Disease | 149 | 2024 | 8717 | 4.720 |
Why?
|
| Genetic Counseling | 32 | 2024 | 634 | 3.530 |
Why?
|
| Disclosure | 25 | 2022 | 755 | 3.340 |
Why?
|
| Genome, Human | 32 | 2024 | 4443 | 2.940 |
Why?
|
| Genetic Predisposition to Disease | 93 | 2024 | 18075 | 2.860 |
Why?
|
| Apolipoproteins E | 36 | 2018 | 1459 | 2.540 |
Why?
|
| Neonatal Screening | 19 | 2024 | 619 | 2.420 |
Why?
|
| Incidental Findings | 11 | 2018 | 698 | 2.180 |
Why?
|
| Apolipoprotein E4 | 23 | 2016 | 709 | 1.680 |
Why?
|
| Sequence Analysis, DNA | 19 | 2024 | 4780 | 1.550 |
Why?
|
| Biological Specimen Banks | 7 | 2021 | 787 | 1.350 |
Why?
|
| Genetics, Medical | 9 | 2023 | 334 | 1.330 |
Why?
|
| Genetic Privacy | 5 | 2018 | 59 | 1.310 |
Why?
|
| Health Knowledge, Attitudes, Practice | 22 | 2024 | 4056 | 1.260 |
Why?
|
| Genetic Diseases, Inborn | 5 | 2017 | 606 | 1.210 |
Why?
|
| Disease | 4 | 2021 | 675 | 1.200 |
Why?
|
| High-Throughput Nucleotide Sequencing | 14 | 2020 | 3666 | 1.180 |
Why?
|
| Family | 19 | 2024 | 3209 | 1.180 |
Why?
|
| Parents | 19 | 2023 | 3593 | 1.160 |
Why?
|
| Genetic Variation | 30 | 2021 | 6612 | 1.090 |
Why?
|
| Histocompatibility Testing | 3 | 2024 | 726 | 1.040 |
Why?
|
| Truth Disclosure | 8 | 2019 | 433 | 1.000 |
Why?
|
| Aminophylline | 2 | 2015 | 41 | 0.960 |
Why?
|
| Genetic Research | 10 | 2021 | 173 | 0.950 |
Why?
|
| Rare Diseases | 4 | 2023 | 630 | 0.940 |
Why?
|
| Sequence Analysis | 2 | 2015 | 240 | 0.910 |
Why?
|
| Chondroitinsulfatases | 1 | 2023 | 16 | 0.860 |
Why?
|
| Humans | 368 | 2024 | 766766 | 0.850 |
Why?
|
| Perception | 8 | 2018 | 1204 | 0.840 |
Why?
|
| Health Literacy | 2 | 2021 | 466 | 0.820 |
Why?
|
| HLA Antigens | 3 | 2024 | 1339 | 0.810 |
Why?
|
| Attitude to Health | 12 | 2019 | 2021 | 0.780 |
Why?
|
| Polymorphism, Single Nucleotide | 38 | 2024 | 16044 | 0.770 |
Why?
|
| Genotype | 43 | 2023 | 13036 | 0.750 |
Why?
|
| Cardiotonic Agents | 2 | 2015 | 541 | 0.750 |
Why?
|
| Multifactorial Inheritance | 5 | 2024 | 1425 | 0.740 |
Why?
|
| Research Subjects | 6 | 2018 | 248 | 0.710 |
Why?
|
| Male | 224 | 2024 | 364142 | 0.710 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 2 | 2015 | 341 | 0.700 |
Why?
|
| Female | 224 | 2024 | 396520 | 0.680 |
Why?
|
| Insurance, Long-Term Care | 3 | 2011 | 18 | 0.680 |
Why?
|
| Cognition Disorders | 24 | 2016 | 3967 | 0.660 |
Why?
|
| Aged, 80 and over | 99 | 2023 | 59550 | 0.660 |
Why?
|
| Biomedical Research | 12 | 2021 | 3459 | 0.650 |
Why?
|
| Aged | 156 | 2024 | 171343 | 0.640 |
Why?
|
| Motivation | 15 | 2022 | 2020 | 0.620 |
Why?
|
| Penetrance | 3 | 2023 | 388 | 0.610 |
Why?
|
| Prenatal Diagnosis | 2 | 2023 | 1271 | 0.610 |
Why?
|
| Risk Assessment | 37 | 2024 | 24295 | 0.600 |
Why?
|
| Decision Making | 16 | 2022 | 3951 | 0.590 |
Why?
|
| Genome-Wide Association Study | 32 | 2024 | 12806 | 0.580 |
Why?
|
| Middle Aged | 134 | 2024 | 223257 | 0.580 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 5 | 2021 | 388 | 0.580 |
Why?
|
| Policy | 1 | 2021 | 512 | 0.570 |
Why?
|
| Adult | 115 | 2024 | 223307 | 0.560 |
Why?
|
| Neuropsychological Tests | 34 | 2014 | 7119 | 0.560 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2021 | 614 | 0.550 |
Why?
|
| Kidney Transplantation | 4 | 2024 | 4278 | 0.520 |
Why?
|
| Research | 2 | 2021 | 1977 | 0.510 |
Why?
|
| Attitude of Health Personnel | 7 | 2020 | 3927 | 0.500 |
Why?
|
| Adoption | 1 | 2016 | 97 | 0.500 |
Why?
|
| Ethics, Medical | 1 | 2021 | 785 | 0.500 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2023 | 1772 | 0.490 |
Why?
|
| Telephone | 2 | 2020 | 629 | 0.470 |
Why?
|
| Health Behavior | 11 | 2018 | 2649 | 0.470 |
Why?
|
| Primary Health Care | 11 | 2023 | 4735 | 0.470 |
Why?
|
| Insurance Selection Bias | 1 | 2015 | 69 | 0.470 |
Why?
|
| Prion Diseases | 1 | 2016 | 99 | 0.470 |
Why?
|
| Public Health | 5 | 2022 | 2681 | 0.470 |
Why?
|
| Cognition | 19 | 2020 | 7057 | 0.460 |
Why?
|
| Prions | 1 | 2016 | 177 | 0.450 |
Why?
|
| Randomized Controlled Trials as Topic | 14 | 2024 | 10384 | 0.450 |
Why?
|
| Infant, Newborn | 29 | 2024 | 26389 | 0.450 |
Why?
|
| Antigens, Human Platelet | 3 | 2019 | 41 | 0.440 |
Why?
|
| Memory | 4 | 2016 | 2192 | 0.440 |
Why?
|
| Consumer Advocacy | 1 | 2014 | 83 | 0.430 |
Why?
|
| Insurance | 1 | 2015 | 115 | 0.430 |
Why?
|
| Hippocampus | 11 | 2017 | 3776 | 0.410 |
Why?
|
| Evidence-Based Practice | 2 | 2016 | 499 | 0.410 |
Why?
|
| United States Food and Drug Administration | 5 | 2023 | 1673 | 0.400 |
Why?
|
| Blood Group Antigens | 3 | 2019 | 183 | 0.400 |
Why?
|
| Mandatory Reporting | 1 | 2013 | 123 | 0.400 |
Why?
|
| Population Surveillance | 5 | 2020 | 2594 | 0.390 |
Why?
|
| Informed Consent | 8 | 2021 | 1010 | 0.390 |
Why?
|
| Evidence-Based Medicine | 2 | 2021 | 3692 | 0.390 |
Why?
|
| Etomidate | 1 | 2014 | 185 | 0.390 |
Why?
|
| Amyloid beta-Peptides | 11 | 2023 | 3887 | 0.380 |
Why?
|
| Research Report | 1 | 2015 | 367 | 0.380 |
Why?
|
| Disease Progression | 27 | 2023 | 13640 | 0.370 |
Why?
|
| Risk Factors | 55 | 2024 | 74881 | 0.370 |
Why?
|
| Mental Recall | 4 | 2012 | 1218 | 0.370 |
Why?
|
| Patient Education as Topic | 8 | 2018 | 2334 | 0.370 |
Why?
|
| Physicians | 6 | 2023 | 4591 | 0.370 |
Why?
|
| Anesthetics, Intravenous | 1 | 2014 | 396 | 0.360 |
Why?
|
| Family Health | 4 | 2010 | 1254 | 0.360 |
Why?
|
| Brain | 28 | 2024 | 27159 | 0.360 |
Why?
|
| Mass Screening | 6 | 2022 | 5454 | 0.360 |
Why?
|
| Information Dissemination | 6 | 2024 | 1142 | 0.360 |
Why?
|
| Patient Preference | 7 | 2018 | 946 | 0.360 |
Why?
|
| Interinstitutional Relations | 1 | 2012 | 235 | 0.350 |
Why?
|
| Longitudinal Studies | 23 | 2020 | 14762 | 0.350 |
Why?
|
| Ethylene Glycols | 4 | 2018 | 196 | 0.350 |
Why?
|
| Flurbiprofen | 1 | 2009 | 21 | 0.350 |
Why?
|
| Attitude | 4 | 2023 | 768 | 0.340 |
Why?
|
| Mutation | 12 | 2023 | 30213 | 0.340 |
Why?
|
| Algorithms | 8 | 2024 | 14072 | 0.340 |
Why?
|
| Health Communication | 1 | 2013 | 216 | 0.330 |
Why?
|
| United States | 45 | 2024 | 72951 | 0.330 |
Why?
|
| Clinical Trials as Topic | 10 | 2024 | 8045 | 0.330 |
Why?
|
| Pedigree | 10 | 2015 | 4539 | 0.330 |
Why?
|
| Academies and Institutes | 1 | 2012 | 326 | 0.330 |
Why?
|
| Aging | 11 | 2015 | 8731 | 0.320 |
Why?
|
| Communication | 11 | 2024 | 3905 | 0.320 |
Why?
|
| Prescription Drugs | 1 | 2016 | 634 | 0.320 |
Why?
|
| Comprehension | 6 | 2018 | 638 | 0.320 |
Why?
|
| Self Disclosure | 1 | 2009 | 248 | 0.310 |
Why?
|
| Blood Grouping and Crossmatching | 2 | 2019 | 99 | 0.310 |
Why?
|
| Presenilins | 1 | 2008 | 51 | 0.310 |
Why?
|
| Employment | 1 | 2015 | 1110 | 0.300 |
Why?
|
| Age of Onset | 15 | 2019 | 3342 | 0.300 |
Why?
|
| Genetic Loci | 8 | 2020 | 2630 | 0.300 |
Why?
|
| Human Genome Project | 1 | 2008 | 202 | 0.290 |
Why?
|
| Government | 1 | 2008 | 161 | 0.290 |
Why?
|
| Ethylene Glycol | 1 | 2007 | 31 | 0.290 |
Why?
|
| Risk | 11 | 2016 | 9602 | 0.290 |
Why?
|
| Postpartum Period | 1 | 2014 | 1195 | 0.290 |
Why?
|
| Private Sector | 2 | 2011 | 396 | 0.290 |
Why?
|
| Civil Rights | 1 | 2008 | 129 | 0.280 |
Why?
|
| Methanol | 1 | 2007 | 91 | 0.280 |
Why?
|
| Young Adult | 31 | 2021 | 59939 | 0.280 |
Why?
|
| Antidotes | 1 | 2007 | 138 | 0.270 |
Why?
|
| Medical History Taking | 4 | 2018 | 779 | 0.270 |
Why?
|
| Genome | 4 | 2022 | 1752 | 0.270 |
Why?
|
| Pharmacogenetics | 7 | 2023 | 682 | 0.260 |
Why?
|
| Fluorine Radioisotopes | 2 | 2018 | 405 | 0.260 |
Why?
|
| Solvents | 1 | 2007 | 299 | 0.260 |
Why?
|
| Computational Biology | 7 | 2019 | 3564 | 0.260 |
Why?
|
| Graft Survival | 4 | 2024 | 3904 | 0.260 |
Why?
|
| Dementia | 9 | 2012 | 2741 | 0.260 |
Why?
|
| Aniline Compounds | 4 | 2018 | 1079 | 0.260 |
Why?
|
| Cooperative Behavior | 2 | 2018 | 1512 | 0.260 |
Why?
|
| Health Care Costs | 5 | 2019 | 3242 | 0.260 |
Why?
|
| Intubation, Intratracheal | 1 | 2014 | 1359 | 0.260 |
Why?
|
| Adaptation, Psychological | 4 | 2013 | 2662 | 0.250 |
Why?
|
| Neoplasms | 6 | 2022 | 22350 | 0.250 |
Why?
|
| Personal Satisfaction | 5 | 2018 | 642 | 0.250 |
Why?
|
| Pyrazoles | 4 | 2011 | 2030 | 0.250 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2009 | 616 | 0.250 |
Why?
|
| Wounds and Injuries | 2 | 2019 | 2513 | 0.250 |
Why?
|
| Physicians, Primary Care | 3 | 2018 | 622 | 0.250 |
Why?
|
| Geriatric Assessment | 9 | 2013 | 1422 | 0.250 |
Why?
|
| Adult Children | 1 | 2005 | 104 | 0.240 |
Why?
|
| Physician-Patient Relations | 6 | 2018 | 3266 | 0.240 |
Why?
|
| Naproxen | 3 | 2011 | 101 | 0.230 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2023 | 3250 | 0.230 |
Why?
|
| Prejudice | 1 | 2008 | 568 | 0.230 |
Why?
|
| Research Design | 7 | 2014 | 6207 | 0.220 |
Why?
|
| Cohort Studies | 25 | 2024 | 41710 | 0.220 |
Why?
|
| tau Proteins | 7 | 2023 | 2107 | 0.220 |
Why?
|
| Multicenter Studies as Topic | 5 | 2024 | 1733 | 0.220 |
Why?
|
| Amino Acid Transport System y+L | 1 | 2023 | 17 | 0.220 |
Why?
|
| Cardiovascular Diseases | 8 | 2019 | 15657 | 0.220 |
Why?
|
| Phenotype | 15 | 2023 | 16724 | 0.210 |
Why?
|
| Myocardial Perfusion Imaging | 2 | 2019 | 669 | 0.210 |
Why?
|
| Bradycardia | 2 | 2015 | 304 | 0.200 |
Why?
|
| Fabry Disease | 1 | 2023 | 89 | 0.200 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3110 | 0.200 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2023 | 105 | 0.200 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3232 | 0.200 |
Why?
|
| Nova Scotia | 3 | 2019 | 33 | 0.200 |
Why?
|
| Professional-Patient Relations | 3 | 2017 | 724 | 0.200 |
Why?
|
| Apolipoprotein E3 | 4 | 2013 | 105 | 0.200 |
Why?
|
| Factor Analysis, Statistical | 3 | 2021 | 1001 | 0.200 |
Why?
|
| Genetic Association Studies | 7 | 2021 | 2746 | 0.200 |
Why?
|
| Duty to Recontact | 1 | 2021 | 19 | 0.200 |
Why?
|
| Arthritis, Rheumatoid | 4 | 2018 | 3788 | 0.190 |
Why?
|
| Antiporters | 1 | 2023 | 275 | 0.190 |
Why?
|
| Politics | 1 | 2008 | 821 | 0.190 |
Why?
|
| National Human Genome Research Institute (U.S.) | 3 | 2016 | 22 | 0.190 |
Why?
|
| Health Education | 3 | 2018 | 1060 | 0.190 |
Why?
|
| Affect | 4 | 2013 | 1494 | 0.190 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2023 | 437 | 0.190 |
Why?
|
| Mental Status Schedule | 7 | 2011 | 315 | 0.190 |
Why?
|
| Stress, Psychological | 7 | 2019 | 4527 | 0.180 |
Why?
|
| Laboratories | 2 | 2016 | 463 | 0.180 |
Why?
|
| Access to Information | 2 | 2017 | 317 | 0.180 |
Why?
|
| Data Collection | 9 | 2014 | 3321 | 0.180 |
Why?
|
| Membrane Transport Proteins | 4 | 2015 | 1029 | 0.180 |
Why?
|
| MNSs Blood-Group System | 1 | 2020 | 7 | 0.180 |
Why?
|
| Educational Status | 9 | 2015 | 2510 | 0.180 |
Why?
|
| Reproducibility of Results | 13 | 2021 | 20144 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 7431 | 0.170 |
Why?
|
| Gastritis | 1 | 2022 | 199 | 0.170 |
Why?
|
| HLA-DQ Antigens | 1 | 2020 | 190 | 0.170 |
Why?
|
| HLA-A Antigens | 1 | 2020 | 223 | 0.170 |
Why?
|
| Fluid Therapy | 2 | 2016 | 587 | 0.170 |
Why?
|
| Amnesia | 2 | 2015 | 257 | 0.170 |
Why?
|
| Uncertainty | 4 | 2019 | 764 | 0.170 |
Why?
|
| Proxy | 2 | 2016 | 150 | 0.170 |
Why?
|
| Population Groups | 2 | 2022 | 209 | 0.170 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2022 | 249 | 0.170 |
Why?
|
| Tissue Donors | 3 | 2024 | 2392 | 0.170 |
Why?
|
| Clinical Medicine | 1 | 2021 | 145 | 0.160 |
Why?
|
| Executive Function | 2 | 2016 | 1396 | 0.160 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 5368 | 0.160 |
Why?
|
| Child | 25 | 2022 | 80668 | 0.160 |
Why?
|
| Colorectal Neoplasms | 4 | 2015 | 6962 | 0.160 |
Why?
|
| Databases as Topic | 2 | 2019 | 472 | 0.160 |
Why?
|
| Confidentiality | 4 | 2019 | 607 | 0.160 |
Why?
|
| HLA-B Antigens | 1 | 2020 | 330 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2011 | 2270 | 0.160 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 3721 | 0.160 |
Why?
|
| Primary Prevention | 1 | 2006 | 1188 | 0.160 |
Why?
|
| Cholesterol, LDL | 2 | 2020 | 2392 | 0.160 |
Why?
|
| HLA-DR Antigens | 1 | 2020 | 609 | 0.160 |
Why?
|
| Workflow | 2 | 2022 | 859 | 0.160 |
Why?
|
| Insurance Coverage | 2 | 2021 | 1945 | 0.160 |
Why?
|
| Biotinidase | 1 | 2018 | 17 | 0.160 |
Why?
|
| Personal Autonomy | 3 | 2019 | 316 | 0.160 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2013 | 833 | 0.160 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2017 | 2902 | 0.150 |
Why?
|
| Traumatology | 1 | 2019 | 101 | 0.150 |
Why?
|
| Ambulances | 1 | 2019 | 94 | 0.150 |
Why?
|
| Aryldialkylphosphatase | 2 | 2010 | 64 | 0.150 |
Why?
|
| Age Factors | 18 | 2019 | 18397 | 0.150 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2019 | 766 | 0.150 |
Why?
|
| Severity of Illness Index | 14 | 2020 | 15908 | 0.150 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 2018 | 64 | 0.150 |
Why?
|
| Transportation of Patients | 1 | 2019 | 177 | 0.150 |
Why?
|
| Life Style | 6 | 2016 | 3926 | 0.150 |
Why?
|
| Organ Size | 6 | 2024 | 2261 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2023 | 12245 | 0.150 |
Why?
|
| Research Personnel | 2 | 2013 | 589 | 0.150 |
Why?
|
| Shock, Septic | 2 | 2016 | 772 | 0.140 |
Why?
|
| Case-Control Studies | 17 | 2019 | 22248 | 0.140 |
Why?
|
| Genome, Mitochondrial | 1 | 2018 | 68 | 0.140 |
Why?
|
| Atrophy | 8 | 2015 | 1631 | 0.140 |
Why?
|
| LDL-Receptor Related Proteins | 2 | 2008 | 118 | 0.140 |
Why?
|
| Cerebral Cortex | 4 | 2020 | 5753 | 0.140 |
Why?
|
| Genes, BRCA2 | 2 | 2019 | 591 | 0.140 |
Why?
|
| Positron-Emission Tomography | 5 | 2024 | 6550 | 0.140 |
Why?
|
| Patient Satisfaction | 4 | 2018 | 3485 | 0.140 |
Why?
|
| Forms and Records Control | 1 | 2018 | 158 | 0.140 |
Why?
|
| Information Storage and Retrieval | 1 | 2023 | 832 | 0.140 |
Why?
|
| Germ Cells | 1 | 2021 | 645 | 0.140 |
Why?
|
| Emotions | 4 | 2019 | 2758 | 0.140 |
Why?
|
| Phospholipase C gamma | 1 | 2017 | 130 | 0.140 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2012 | 453 | 0.140 |
Why?
|
| Multigene Family | 3 | 2011 | 1081 | 0.140 |
Why?
|
| Multivariate Analysis | 6 | 2016 | 12064 | 0.140 |
Why?
|
| Activities of Daily Living | 4 | 2012 | 2429 | 0.140 |
Why?
|
| Dietary Supplements | 1 | 2010 | 3429 | 0.140 |
Why?
|
| Adolescent | 24 | 2020 | 88904 | 0.140 |
Why?
|
| Attention | 2 | 2010 | 2413 | 0.140 |
Why?
|
| Health Personnel | 5 | 2023 | 3384 | 0.130 |
Why?
|
| Trauma Centers | 2 | 2019 | 950 | 0.130 |
Why?
|
| Peptide Fragments | 4 | 2017 | 5143 | 0.130 |
Why?
|
| Depression, Postpartum | 1 | 2021 | 354 | 0.130 |
Why?
|
| Follow-Up Studies | 14 | 2016 | 39309 | 0.130 |
Why?
|
| Software | 6 | 2019 | 4466 | 0.130 |
Why?
|
| Concept Formation | 2 | 2015 | 159 | 0.130 |
Why?
|
| Retinitis Pigmentosa | 1 | 2020 | 395 | 0.130 |
Why?
|
| Fetus | 1 | 2023 | 1878 | 0.130 |
Why?
|
| Sex Factors | 12 | 2019 | 10619 | 0.130 |
Why?
|
| Diagnosis, Computer-Assisted | 3 | 1997 | 698 | 0.130 |
Why?
|
| Metagenomics | 1 | 2019 | 473 | 0.130 |
Why?
|
| Interleukin-1 Receptor Accessory Protein | 1 | 2015 | 5 | 0.130 |
Why?
|
| Newfoundland and Labrador | 2 | 2010 | 11 | 0.130 |
Why?
|
| Cardiomyopathies | 3 | 2019 | 2059 | 0.130 |
Why?
|
| Heterozygote | 7 | 2019 | 2795 | 0.130 |
Why?
|
| Homozygote | 3 | 2015 | 1775 | 0.130 |
Why?
|
| Logistic Models | 9 | 2019 | 13278 | 0.130 |
Why?
|
| Alleles | 9 | 2018 | 6895 | 0.130 |
Why?
|
| Medical Informatics | 2 | 2014 | 744 | 0.130 |
Why?
|
| Health | 1 | 2019 | 397 | 0.130 |
Why?
|
| Internationality | 1 | 2021 | 1006 | 0.130 |
Why?
|
| Prospective Studies | 14 | 2022 | 54871 | 0.130 |
Why?
|
| ABO Blood-Group System | 1 | 2018 | 381 | 0.120 |
Why?
|
| Specimen Handling | 1 | 2020 | 706 | 0.120 |
Why?
|
| Anxiety | 7 | 2019 | 4670 | 0.120 |
Why?
|
| Infant | 8 | 2024 | 36461 | 0.120 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2017 | 1336 | 0.120 |
Why?
|
| Pancreatitis | 1 | 2022 | 1087 | 0.120 |
Why?
|
| Erythrocytes | 3 | 2019 | 2412 | 0.120 |
Why?
|
| Sulfonamides | 3 | 2011 | 1982 | 0.120 |
Why?
|
| Depression | 8 | 2021 | 8228 | 0.120 |
Why?
|
| Regression Analysis | 7 | 2013 | 6329 | 0.120 |
Why?
|
| Gene Frequency | 6 | 2017 | 3624 | 0.120 |
Why?
|
| Neurology | 2 | 2010 | 785 | 0.120 |
Why?
|
| Behavioral Medicine | 1 | 1995 | 49 | 0.120 |
Why?
|
| Amyloid | 2 | 2021 | 849 | 0.120 |
Why?
|
| Cerebrovascular Disorders | 4 | 2015 | 1479 | 0.120 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2016 | 238 | 0.120 |
Why?
|
| Learning | 3 | 2010 | 1754 | 0.120 |
Why?
|
| Exons | 1 | 2020 | 2392 | 0.110 |
Why?
|
| Predictive Value of Tests | 13 | 2017 | 15416 | 0.110 |
Why?
|
| Early Diagnosis | 3 | 2015 | 1186 | 0.110 |
Why?
|
| Health Care Surveys | 4 | 2018 | 2425 | 0.110 |
Why?
|
| Coronary Artery Disease | 4 | 2019 | 6558 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 5 | 2021 | 5536 | 0.110 |
Why?
|
| Genes, Dominant | 1 | 2016 | 855 | 0.110 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2023 | 1178 | 0.110 |
Why?
|
| Information Seeking Behavior | 1 | 2015 | 116 | 0.110 |
Why?
|
| Drug Approval | 1 | 2021 | 820 | 0.110 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2015 | 566 | 0.110 |
Why?
|
| Butyrylcholinesterase | 1 | 2013 | 21 | 0.110 |
Why?
|
| Accidents, Traffic | 1 | 2019 | 818 | 0.110 |
Why?
|
| Injections, Intravenous | 1 | 2015 | 1377 | 0.110 |
Why?
|
| Isoxazoles | 1 | 1995 | 233 | 0.110 |
Why?
|
| Guidelines as Topic | 3 | 2016 | 1394 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 1994 | 313 | 0.110 |
Why?
|
| Random Allocation | 2 | 2010 | 2394 | 0.110 |
Why?
|
| Military Personnel | 2 | 2020 | 1260 | 0.110 |
Why?
|
| Science | 1 | 2016 | 234 | 0.110 |
Why?
|
| Botulinum Toxins | 1 | 1995 | 191 | 0.110 |
Why?
|
| Diagnostic Imaging | 4 | 2012 | 3531 | 0.110 |
Why?
|
| Odds Ratio | 7 | 2017 | 9661 | 0.100 |
Why?
|
| Pancreatitis, Alcoholic | 1 | 2012 | 28 | 0.100 |
Why?
|
| Public Policy | 1 | 2017 | 551 | 0.100 |
Why?
|
| Immunity | 1 | 2019 | 1002 | 0.100 |
Why?
|
| Chromosome Mapping | 5 | 2021 | 4619 | 0.100 |
Why?
|
| Trypsinogen | 1 | 2012 | 84 | 0.100 |
Why?
|
| Psychometrics | 2 | 2021 | 3060 | 0.100 |
Why?
|
| Genes, BRCA1 | 2 | 2014 | 753 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2020 | 3230 | 0.100 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2018 | 3684 | 0.100 |
Why?
|
| Cholinesterase Inhibitors | 3 | 2012 | 242 | 0.100 |
Why?
|
| Gene Deletion | 1 | 2020 | 2669 | 0.100 |
Why?
|
| Health Resources | 1 | 2019 | 951 | 0.100 |
Why?
|
| Twins, Dizygotic | 1 | 2013 | 236 | 0.100 |
Why?
|
| Radionuclide Imaging | 5 | 2016 | 1986 | 0.100 |
Why?
|
| Presenilin-1 | 1 | 2016 | 665 | 0.100 |
Why?
|
| Calcineurin | 1 | 2013 | 235 | 0.100 |
Why?
|
| Valproic Acid | 1 | 1995 | 444 | 0.100 |
Why?
|
| Siblings | 3 | 2019 | 828 | 0.100 |
Why?
|
| Georgia | 4 | 2013 | 186 | 0.100 |
Why?
|
| Trypsin | 1 | 2012 | 490 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 2 | 2019 | 2693 | 0.100 |
Why?
|
| Claudins | 1 | 2012 | 116 | 0.100 |
Why?
|
| Memory Disorders | 4 | 2014 | 1193 | 0.100 |
Why?
|
| Blood Preservation | 1 | 2012 | 169 | 0.100 |
Why?
|
| Probability | 3 | 2016 | 2476 | 0.100 |
Why?
|
| Poly T | 1 | 2011 | 6 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2013 | 412 | 0.100 |
Why?
|
| Registries | 4 | 2024 | 8351 | 0.100 |
Why?
|
| Speech Perception | 1 | 1996 | 512 | 0.100 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2013 | 165 | 0.100 |
Why?
|
| Resuscitation | 1 | 2016 | 681 | 0.100 |
Why?
|
| Cephalometry | 2 | 2010 | 380 | 0.090 |
Why?
|
| Receptor, EphA1 | 1 | 2011 | 20 | 0.090 |
Why?
|
| Polymorphism, Genetic | 4 | 2009 | 4249 | 0.090 |
Why?
|
| Age Distribution | 4 | 2011 | 2869 | 0.090 |
Why?
|
| Depressive Disorder | 2 | 2007 | 3715 | 0.090 |
Why?
|
| Graft Rejection | 2 | 2024 | 4504 | 0.090 |
Why?
|
| Counseling | 2 | 2020 | 1552 | 0.090 |
Why?
|
| Dystonia | 1 | 1995 | 378 | 0.090 |
Why?
|
| Interviews as Topic | 3 | 2013 | 2741 | 0.090 |
Why?
|
| Amyloid beta-Protein Precursor | 2 | 2015 | 1117 | 0.090 |
Why?
|
| Blood Specimen Collection | 1 | 2012 | 238 | 0.090 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2011 | 200 | 0.090 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2013 | 428 | 0.090 |
Why?
|
| Twins, Monozygotic | 1 | 2013 | 471 | 0.090 |
Why?
|
| Databases, Bibliographic | 3 | 2016 | 128 | 0.090 |
Why?
|
| Medical Errors | 1 | 2019 | 1260 | 0.090 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2012 | 205 | 0.090 |
Why?
|
| Receptors, Immunologic | 1 | 2017 | 1418 | 0.090 |
Why?
|
| Memantine | 1 | 2012 | 110 | 0.090 |
Why?
|
| DNA | 2 | 2021 | 7208 | 0.090 |
Why?
|
| New York City | 5 | 2012 | 736 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2020 | 36567 | 0.090 |
Why?
|
| Hospitalization | 6 | 2019 | 10823 | 0.090 |
Why?
|
| Pyrrolidines | 1 | 1992 | 339 | 0.090 |
Why?
|
| Molecular Typing | 1 | 2011 | 115 | 0.090 |
Why?
|
| Plaque, Amyloid | 2 | 2013 | 769 | 0.090 |
Why?
|
| Independent Living | 2 | 2011 | 584 | 0.090 |
Why?
|
| Urban Population | 2 | 2009 | 2040 | 0.090 |
Why?
|
| Drosophila melanogaster | 1 | 2019 | 1725 | 0.090 |
Why?
|
| Ethics Committees, Research | 1 | 2012 | 196 | 0.090 |
Why?
|
| Galactosemias | 1 | 2011 | 124 | 0.090 |
Why?
|
| Caregivers | 3 | 2013 | 2303 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2005 | 5091 | 0.090 |
Why?
|
| Pilot Projects | 8 | 2018 | 8728 | 0.080 |
Why?
|
| Assisted Living Facilities | 1 | 2010 | 27 | 0.080 |
Why?
|
| Founder Effect | 1 | 2010 | 185 | 0.080 |
Why?
|
| Early Detection of Cancer | 2 | 2021 | 3236 | 0.080 |
Why?
|
| Patient-Centered Care | 3 | 2016 | 1445 | 0.080 |
Why?
|
| Influenza, Human | 2 | 2012 | 1543 | 0.080 |
Why?
|
| Pregnancy | 4 | 2023 | 30237 | 0.080 |
Why?
|
| Waste Disposal, Fluid | 1 | 2009 | 34 | 0.080 |
Why?
|
| Linear Models | 5 | 2013 | 5874 | 0.080 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2011 | 281 | 0.080 |
Why?
|
| Technology Transfer | 1 | 2009 | 41 | 0.080 |
Why?
|
| Personality | 1 | 2013 | 560 | 0.080 |
Why?
|
| Acetylcholinesterase | 1 | 1989 | 151 | 0.080 |
Why?
|
| Canada | 4 | 2019 | 2126 | 0.080 |
Why?
|
| Publications | 1 | 2012 | 195 | 0.080 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2012 | 451 | 0.080 |
Why?
|
| Patient Selection | 4 | 2018 | 4252 | 0.080 |
Why?
|
| Soil Pollutants | 1 | 2009 | 77 | 0.080 |
Why?
|
| Water Purification | 1 | 2009 | 61 | 0.080 |
Why?
|
| Chromatin | 1 | 2021 | 2977 | 0.080 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 932 | 0.080 |
Why?
|
| Medication Adherence | 1 | 2020 | 2190 | 0.080 |
Why?
|
| Genetic Linkage | 1 | 1994 | 2342 | 0.080 |
Why?
|
| Psychiatric Status Rating Scales | 7 | 2013 | 6020 | 0.080 |
Why?
|
| Databases, Genetic | 4 | 2018 | 1756 | 0.080 |
Why?
|
| Brain Chemistry | 1 | 2012 | 951 | 0.080 |
Why?
|
| Serum Albumin | 1 | 2011 | 675 | 0.080 |
Why?
|
| Microglia | 1 | 2017 | 1370 | 0.080 |
Why?
|
| Professional Practice | 1 | 2010 | 314 | 0.080 |
Why?
|
| Life Change Events | 1 | 2013 | 956 | 0.070 |
Why?
|
| Trail Making Test | 1 | 2008 | 57 | 0.070 |
Why?
|
| Washington | 1 | 2008 | 315 | 0.070 |
Why?
|
| Survival Analysis | 3 | 2020 | 10100 | 0.070 |
Why?
|
| Culture | 1 | 2012 | 622 | 0.070 |
Why?
|
| Organizational Objectives | 1 | 2010 | 426 | 0.070 |
Why?
|
| Lipids | 1 | 2019 | 3319 | 0.070 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2010 | 244 | 0.070 |
Why?
|
| Chi-Square Distribution | 2 | 2015 | 3432 | 0.070 |
Why?
|
| Temporal Lobe | 3 | 2012 | 1716 | 0.070 |
Why?
|
| Piperidines | 2 | 1999 | 1663 | 0.070 |
Why?
|
| Skilled Nursing Facilities | 1 | 2011 | 406 | 0.070 |
Why?
|
| DNA Mismatch Repair | 1 | 2010 | 432 | 0.070 |
Why?
|
| Health Services for the Aged | 1 | 2010 | 264 | 0.070 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2007 | 113 | 0.070 |
Why?
|
| Family Relations | 1 | 2009 | 318 | 0.070 |
Why?
|
| Emergency Medicine | 1 | 2016 | 1220 | 0.070 |
Why?
|
| Prealbumin | 1 | 2009 | 259 | 0.070 |
Why?
|
| Linkage Disequilibrium | 4 | 2017 | 1996 | 0.070 |
Why?
|
| Genetic Markers | 2 | 2008 | 2603 | 0.070 |
Why?
|
| Analysis of Variance | 6 | 2011 | 6214 | 0.070 |
Why?
|
| Conflict of Interest | 1 | 2012 | 556 | 0.070 |
Why?
|
| Microsatellite Instability | 1 | 2010 | 726 | 0.070 |
Why?
|
| Drug Industry | 1 | 2013 | 791 | 0.070 |
Why?
|
| Membrane Glycoproteins | 1 | 2017 | 3702 | 0.070 |
Why?
|
| Sensitivity and Specificity | 6 | 2024 | 14652 | 0.070 |
Why?
|
| Orientation | 2 | 2006 | 314 | 0.070 |
Why?
|
| Cross-Cultural Comparison | 2 | 2006 | 636 | 0.070 |
Why?
|
| Risk Reduction Behavior | 1 | 2013 | 1120 | 0.070 |
Why?
|
| Massachusetts | 2 | 2017 | 8891 | 0.070 |
Why?
|
| Endocrine Disruptors | 1 | 2009 | 264 | 0.070 |
Why?
|
| Double-Blind Method | 5 | 2011 | 12430 | 0.070 |
Why?
|
| Fellowships and Scholarships | 1 | 1995 | 1134 | 0.060 |
Why?
|
| Poisoning | 1 | 2007 | 254 | 0.060 |
Why?
|
| Nuclear Proteins | 2 | 2011 | 5795 | 0.060 |
Why?
|
| Prostatic Neoplasms | 4 | 2023 | 11094 | 0.060 |
Why?
|
| Benzodiazepines | 1 | 2012 | 1137 | 0.060 |
Why?
|
| Mutation, Missense | 2 | 2015 | 2590 | 0.060 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 1989 | 390 | 0.060 |
Why?
|
| Seizures | 2 | 2009 | 2996 | 0.060 |
Why?
|
| Behavior | 1 | 2008 | 538 | 0.060 |
Why?
|
| Water Pollutants, Chemical | 1 | 2009 | 356 | 0.060 |
Why?
|
| Cytoskeletal Proteins | 1 | 2011 | 1325 | 0.060 |
Why?
|
| Psychomotor Agitation | 1 | 2008 | 307 | 0.060 |
Why?
|
| Mental Processes | 1 | 2006 | 242 | 0.060 |
Why?
|
| Injury Severity Score | 2 | 2019 | 1049 | 0.060 |
Why?
|
| Prognosis | 4 | 2020 | 29948 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2017 | 3077 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 1560 | 0.060 |
Why?
|
| Weight Loss | 1 | 2016 | 2712 | 0.060 |
Why?
|
| Haplotypes | 3 | 2019 | 2727 | 0.060 |
Why?
|
| DNA, Neoplasm | 1 | 2010 | 1741 | 0.060 |
Why?
|
| Demography | 3 | 2017 | 1641 | 0.060 |
Why?
|
| Reading | 1 | 2008 | 540 | 0.060 |
Why?
|
| Community Health Services | 1 | 2010 | 659 | 0.060 |
Why?
|
| Intention | 2 | 2018 | 347 | 0.060 |
Why?
|
| Individuality | 1 | 2006 | 303 | 0.060 |
Why?
|
| Muscular Diseases | 2 | 2020 | 551 | 0.060 |
Why?
|
| Utah | 3 | 2011 | 130 | 0.060 |
Why?
|
| Inservice Training | 2 | 2019 | 374 | 0.060 |
Why?
|
| Epilepsies, Partial | 1 | 1988 | 431 | 0.060 |
Why?
|
| Head | 1 | 2010 | 926 | 0.060 |
Why?
|
| Fatigue | 1 | 2011 | 1555 | 0.060 |
Why?
|
| Social Stigma | 1 | 2011 | 788 | 0.060 |
Why?
|
| Publishing | 1 | 2011 | 837 | 0.060 |
Why?
|
| Arabs | 1 | 2006 | 190 | 0.060 |
Why?
|
| Nerve Degeneration | 1 | 2008 | 748 | 0.060 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2007 | 541 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2015 | 2978 | 0.060 |
Why?
|
| Altruism | 1 | 2005 | 211 | 0.050 |
Why?
|
| Health Status | 3 | 2013 | 4087 | 0.050 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2019 | 1143 | 0.050 |
Why?
|
| Depressive Disorder, Major | 1 | 2021 | 4810 | 0.050 |
Why?
|
| Histocompatibility | 1 | 2024 | 327 | 0.050 |
Why?
|
| Physician's Role | 1 | 2010 | 925 | 0.050 |
Why?
|
| Critical Care | 1 | 2016 | 2714 | 0.050 |
Why?
|
| Colonoscopy | 1 | 2011 | 1409 | 0.050 |
Why?
|
| Retrospective Studies | 9 | 2024 | 81635 | 0.050 |
Why?
|
| Smoking | 3 | 2016 | 9077 | 0.050 |
Why?
|
| Heart Arrest | 1 | 2013 | 1516 | 0.050 |
Why?
|
| Time Factors | 8 | 2019 | 40149 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2006 | 707 | 0.050 |
Why?
|
| Medical Records | 1 | 2008 | 1408 | 0.050 |
Why?
|
| Cerebral Arteries | 1 | 2005 | 490 | 0.050 |
Why?
|
| Office Visits | 2 | 2017 | 593 | 0.050 |
Why?
|
| Reference Values | 5 | 2008 | 4913 | 0.050 |
Why?
|
| Obesity | 2 | 2016 | 13090 | 0.050 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2008 | 1241 | 0.050 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2020 | 937 | 0.050 |
Why?
|
| Child of Impaired Parents | 1 | 2006 | 462 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2014 | 2727 | 0.050 |
Why?
|
| Donor Selection | 1 | 2024 | 242 | 0.050 |
Why?
|
| Parkinson Disease | 3 | 2024 | 2884 | 0.050 |
Why?
|
| Visual Perception | 2 | 2012 | 1392 | 0.050 |
Why?
|
| Referral and Consultation | 2 | 2017 | 3618 | 0.050 |
Why?
|
| Brain Injuries | 1 | 2014 | 2053 | 0.050 |
Why?
|
| Pregnancy Complications | 2 | 2016 | 2971 | 0.050 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2024 | 291 | 0.050 |
Why?
|
| Sclerosis | 2 | 2014 | 211 | 0.050 |
Why?
|
| Nursing Homes | 1 | 2010 | 1084 | 0.050 |
Why?
|
| Sodium Chloride | 2 | 2016 | 580 | 0.050 |
Why?
|
| Ethics, Research | 2 | 2015 | 178 | 0.050 |
Why?
|
| Lower Extremity | 1 | 2010 | 1217 | 0.050 |
Why?
|
| Personal Health Services | 2 | 2013 | 24 | 0.050 |
Why?
|
| Parent-Child Relations | 2 | 2021 | 772 | 0.050 |
Why?
|
| Italy | 2 | 2019 | 856 | 0.050 |
Why?
|
| Diet | 2 | 2017 | 8088 | 0.050 |
Why?
|
| Molecular Sequence Annotation | 2 | 2014 | 526 | 0.050 |
Why?
|
| Boston | 4 | 2020 | 9346 | 0.050 |
Why?
|
| Neuroprotective Agents | 1 | 2008 | 956 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 2 | 2010 | 5789 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2016 | 5915 | 0.050 |
Why?
|
| Tissue and Organ Procurement | 2 | 2024 | 987 | 0.050 |
Why?
|
| Ethanol | 1 | 2007 | 1326 | 0.050 |
Why?
|
| Length of Stay | 2 | 2014 | 6490 | 0.040 |
Why?
|
| Simvastatin | 1 | 2023 | 345 | 0.040 |
Why?
|
| Community Health Planning | 2 | 2012 | 164 | 0.040 |
Why?
|
| Nootropic Agents | 2 | 2015 | 159 | 0.040 |
Why?
|
| Diagnostic Errors | 1 | 2008 | 1276 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2014 | 3799 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2010 | 2056 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2011 | 4032 | 0.040 |
Why?
|
| Mood Disorders | 1 | 2007 | 1127 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2017 | 792 | 0.040 |
Why?
|
| Exercise | 1 | 2017 | 5945 | 0.040 |
Why?
|
| Veterans | 1 | 2014 | 2667 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2010 | 1761 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 8735 | 0.040 |
Why?
|
| Hospitals, Pediatric | 3 | 2014 | 1851 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2012 | 2903 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2006 | 1319 | 0.040 |
Why?
|
| Psychomotor Performance | 1 | 2008 | 1885 | 0.040 |
Why?
|
| Gene Expression | 1 | 2012 | 7585 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 5514 | 0.040 |
Why?
|
| Craniocerebral Trauma | 2 | 2003 | 493 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2009 | 1949 | 0.040 |
Why?
|
| Confusion | 2 | 2012 | 278 | 0.040 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2020 | 391 | 0.040 |
Why?
|
| Ribonuclease III | 1 | 2021 | 271 | 0.040 |
Why?
|
| Drowning | 1 | 2019 | 27 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2017 | 746 | 0.040 |
Why?
|
| Australia | 1 | 2022 | 1263 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2021 | 8066 | 0.040 |
Why?
|
| Neurofibrillary Tangles | 2 | 2015 | 457 | 0.040 |
Why?
|
| Spouses | 2 | 2013 | 286 | 0.040 |
Why?
|
| Insurance, Health | 2 | 2008 | 2520 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2002 | 993 | 0.040 |
Why?
|
| Asphyxia | 1 | 2019 | 60 | 0.040 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2019 | 185 | 0.040 |
Why?
|
| Cause of Death | 1 | 2009 | 3716 | 0.040 |
Why?
|
| Antipsychotic Agents | 1 | 2012 | 3078 | 0.040 |
Why?
|
| Muscles | 1 | 2023 | 1576 | 0.040 |
Why?
|
| Duty to Warn | 1 | 2018 | 30 | 0.040 |
Why?
|
| Models, Genetic | 4 | 2013 | 3450 | 0.040 |
Why?
|
| Arctic Regions | 1 | 1998 | 25 | 0.040 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2005 | 1205 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 3601 | 0.040 |
Why?
|
| Membrane Proteins | 2 | 2015 | 7868 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2020 | 354 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2010 | 3957 | 0.040 |
Why?
|
| Internet | 3 | 2016 | 3113 | 0.040 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2021 | 385 | 0.040 |
Why?
|
| Child, Preschool | 6 | 2019 | 42577 | 0.040 |
Why?
|
| Metabolic Diseases | 1 | 2024 | 686 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2007 | 1790 | 0.040 |
Why?
|
| Fires | 1 | 2019 | 170 | 0.040 |
Why?
|
| Harm Reduction | 1 | 2019 | 143 | 0.040 |
Why?
|
| Breast Neoplasms | 4 | 2019 | 21162 | 0.040 |
Why?
|
| Health Policy | 1 | 2010 | 2698 | 0.040 |
Why?
|
| Galactosyltransferases | 1 | 2018 | 283 | 0.030 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2024 | 3724 | 0.030 |
Why?
|
| Mental Disorders | 2 | 2013 | 6869 | 0.030 |
Why?
|
| Hospitals | 2 | 2023 | 3888 | 0.030 |
Why?
|
| Socioeconomic Factors | 4 | 2014 | 7841 | 0.030 |
Why?
|
| Models, Psychological | 2 | 2015 | 823 | 0.030 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2017 | 93 | 0.030 |
Why?
|
| Friends | 1 | 2018 | 150 | 0.030 |
Why?
|
| Parenting | 1 | 2022 | 708 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2017 | 224 | 0.030 |
Why?
|
| Methionine Sulfoxide Reductases | 1 | 2017 | 77 | 0.030 |
Why?
|
| Oncogene Protein v-akt | 1 | 2016 | 130 | 0.030 |
Why?
|
| Plasma Substitutes | 1 | 2016 | 56 | 0.030 |
Why?
|
| Classification | 1 | 2017 | 128 | 0.030 |
Why?
|
| Cardiology Service, Hospital | 1 | 2018 | 242 | 0.030 |
Why?
|
| Genomic Structural Variation | 1 | 2017 | 80 | 0.030 |
Why?
|
| Tropicamide | 1 | 1996 | 22 | 0.030 |
Why?
|
| Gene Duplication | 1 | 2017 | 315 | 0.030 |
Why?
|
| Colloids | 1 | 2016 | 125 | 0.030 |
Why?
|
| Medicaid | 1 | 2010 | 2836 | 0.030 |
Why?
|
| Cardiology | 2 | 2018 | 1701 | 0.030 |
Why?
|
| Isotonic Solutions | 1 | 2016 | 119 | 0.030 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2014 | 4628 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2017 | 350 | 0.030 |
Why?
|
| Parasympatholytics | 1 | 1996 | 89 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2010 | 4427 | 0.030 |
Why?
|
| Prevalence | 4 | 2018 | 15835 | 0.030 |
Why?
|
| Saudi Arabia | 1 | 2016 | 211 | 0.030 |
Why?
|
| Indiana | 1 | 2015 | 93 | 0.030 |
Why?
|
| Epilepsy | 1 | 2011 | 3317 | 0.030 |
Why?
|
| Minnesota | 1 | 2016 | 339 | 0.030 |
Why?
|
| Brain Mapping | 3 | 2020 | 6596 | 0.030 |
Why?
|
| Placebo Effect | 1 | 1999 | 515 | 0.030 |
Why?
|
| Mediator Complex | 1 | 2015 | 106 | 0.030 |
Why?
|
| Chicago | 1 | 2015 | 255 | 0.030 |
Why?
|
| Pupil | 1 | 1996 | 147 | 0.030 |
Why?
|
| Chlorpromazine | 1 | 1995 | 111 | 0.030 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 13485 | 0.030 |
Why?
|
| Comorbidity | 4 | 2016 | 10580 | 0.030 |
Why?
|
| Syndrome | 1 | 2021 | 3271 | 0.030 |
Why?
|
| Genetics | 1 | 2015 | 114 | 0.030 |
Why?
|
| Neck Muscles | 1 | 1995 | 100 | 0.030 |
Why?
|
| Neurodegenerative Diseases | 2 | 2015 | 1089 | 0.030 |
Why?
|
| Amino Acids | 1 | 2020 | 1711 | 0.030 |
Why?
|
| Phenytoin | 1 | 1995 | 189 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 588 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2019 | 1838 | 0.030 |
Why?
|
| Phenylketonurias | 1 | 2015 | 128 | 0.030 |
Why?
|
| Tape Recording | 1 | 2013 | 77 | 0.030 |
Why?
|
| Income | 1 | 2022 | 1875 | 0.030 |
Why?
|
| Incidence | 5 | 2011 | 21525 | 0.030 |
Why?
|
| Program Development | 2 | 2010 | 1297 | 0.030 |
Why?
|
| Putamen | 1 | 2015 | 288 | 0.030 |
Why?
|
| Social Class | 1 | 2003 | 2007 | 0.030 |
Why?
|
| RNA Splicing | 1 | 2018 | 903 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2022 | 1885 | 0.030 |
Why?
|
| Acetamides | 1 | 2015 | 260 | 0.030 |
Why?
|
| Albumins | 1 | 2016 | 578 | 0.030 |
Why?
|
| Health Status Indicators | 2 | 2011 | 968 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2011 | 2921 | 0.030 |
Why?
|
| Caudate Nucleus | 1 | 2015 | 388 | 0.030 |
Why?
|
| Adenomatous Polyps | 1 | 1994 | 109 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2019 | 1667 | 0.030 |
Why?
|
| Cross-Sectional Studies | 4 | 2012 | 26310 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2017 | 2746 | 0.030 |
Why?
|
| Genes, Recessive | 1 | 2015 | 625 | 0.030 |
Why?
|
| Lost to Follow-Up | 1 | 2013 | 124 | 0.030 |
Why?
|
| Chromosomes | 1 | 2016 | 578 | 0.030 |
Why?
|
| Government Regulation | 1 | 2017 | 525 | 0.030 |
Why?
|
| Legislation as Topic | 1 | 2012 | 76 | 0.030 |
Why?
|
| Sex Characteristics | 2 | 2015 | 2645 | 0.030 |
Why?
|
| Risperidone | 1 | 1995 | 383 | 0.030 |
Why?
|
| Self-Injurious Behavior | 1 | 2019 | 571 | 0.030 |
Why?
|
| Binding Sites | 1 | 2021 | 6012 | 0.030 |
Why?
|
| Sulfonylurea Compounds | 1 | 2014 | 220 | 0.030 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2013 | 196 | 0.020 |
Why?
|
| Overweight | 2 | 2014 | 2446 | 0.020 |
Why?
|
| Endophenotypes | 1 | 2014 | 258 | 0.020 |
Why?
|
| Patients | 1 | 2018 | 908 | 0.020 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2013 | 146 | 0.020 |
Why?
|
| Social Marketing | 1 | 2011 | 51 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2014 | 957 | 0.020 |
Why?
|
| Proportional Hazards Models | 4 | 2011 | 12534 | 0.020 |
Why?
|
| Sweden | 1 | 2015 | 1382 | 0.020 |
Why?
|
| Quality of Life | 1 | 2013 | 13476 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2017 | 1071 | 0.020 |
Why?
|
| Mutagenesis, Insertional | 1 | 2014 | 663 | 0.020 |
Why?
|
| Cholesterol | 1 | 2020 | 2903 | 0.020 |
Why?
|
| Diabetes Mellitus | 2 | 2007 | 5887 | 0.020 |
Why?
|
| Acute Disease | 1 | 2022 | 7241 | 0.020 |
Why?
|
| UTP-Hexose-1-Phosphate Uridylyltransferase | 1 | 2011 | 67 | 0.020 |
Why?
|
| Problem Solving | 1 | 1994 | 442 | 0.020 |
Why?
|
| Qualitative Research | 2 | 2017 | 3138 | 0.020 |
Why?
|
| Apolipoprotein E2 | 1 | 2011 | 134 | 0.020 |
Why?
|
| Tissue Banks | 1 | 2012 | 183 | 0.020 |
Why?
|
| Arteriosclerosis | 1 | 2015 | 1055 | 0.020 |
Why?
|
| Education | 1 | 2014 | 531 | 0.020 |
Why?
|
| Antihypertensive Agents | 2 | 2013 | 2030 | 0.020 |
Why?
|
| Accidental Falls | 1 | 2019 | 1078 | 0.020 |
Why?
|
| Mothers | 1 | 2021 | 2208 | 0.020 |
Why?
|
| Sex Distribution | 2 | 2011 | 2274 | 0.020 |
Why?
|
| Monomeric Clathrin Assembly Proteins | 1 | 2010 | 24 | 0.020 |
Why?
|
| Myocardial Infarction | 3 | 2008 | 11513 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2011 | 299 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 1895 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2005 | 9357 | 0.020 |
Why?
|
| Americas | 1 | 2010 | 110 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2013 | 1019 | 0.020 |
Why?
|
| Skull | 1 | 2015 | 819 | 0.020 |
Why?
|
| Directive Counseling | 1 | 2011 | 171 | 0.020 |
Why?
|
| Observation | 1 | 2012 | 310 | 0.020 |
Why?
|
| Blood Vessels | 1 | 2015 | 1111 | 0.020 |
Why?
|
| Poaceae | 1 | 2009 | 25 | 0.020 |
Why?
|
| Survival | 1 | 2010 | 160 | 0.020 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2017 | 858 | 0.020 |
Why?
|
| Judgment | 1 | 2012 | 270 | 0.020 |
Why?
|
| Critical Illness | 1 | 2022 | 2750 | 0.020 |
Why?
|
| Biodegradation, Environmental | 1 | 2009 | 220 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2014 | 3053 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2017 | 2201 | 0.020 |
Why?
|
| Pregnancy, Multiple | 1 | 1990 | 216 | 0.020 |
Why?
|
| Oral Health | 1 | 2014 | 493 | 0.020 |
Why?
|
| Cerebral Decortication | 1 | 1988 | 11 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2015 | 1776 | 0.020 |
Why?
|
| Coronary Artery Bypass | 2 | 2008 | 2188 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2014 | 830 | 0.020 |
Why?
|
| Autopsy | 1 | 2012 | 1011 | 0.020 |
Why?
|
| Authorship | 1 | 2011 | 289 | 0.020 |
Why?
|
| Health Services Needs and Demand | 2 | 2006 | 1404 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 1989 | 697 | 0.020 |
Why?
|
| Interview, Psychological | 1 | 2011 | 810 | 0.020 |
Why?
|
| Placebos | 1 | 1992 | 1659 | 0.020 |
Why?
|
| Greece | 1 | 2009 | 341 | 0.020 |
Why?
|
| Myocardial Ischemia | 1 | 2019 | 2132 | 0.020 |
Why?
|
| Sample Size | 1 | 2011 | 844 | 0.020 |
Why?
|
| Religion | 1 | 2011 | 376 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2016 | 2001 | 0.020 |
Why?
|
| Psychosurgery | 1 | 1988 | 86 | 0.020 |
Why?
|
| Nerve Net | 1 | 2010 | 2307 | 0.020 |
Why?
|
| Telomere | 1 | 1994 | 943 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2010 | 572 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2012 | 1211 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2013 | 1437 | 0.020 |
Why?
|
| Hospitals, Urban | 1 | 2010 | 494 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2018 | 2465 | 0.020 |
Why?
|
| Marriage | 1 | 2009 | 351 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 1994 | 1408 | 0.020 |
Why?
|
| Protease Nexins | 1 | 2007 | 39 | 0.020 |
Why?
|
| Hospitals, Community | 1 | 2010 | 363 | 0.020 |
Why?
|
| Memory, Short-Term | 1 | 1994 | 1004 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 2881 | 0.020 |
Why?
|
| Rural Population | 1 | 1998 | 2321 | 0.020 |
Why?
|
| Patient Participation | 1 | 2016 | 1445 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2013 | 2717 | 0.020 |
Why?
|
| Germany | 1 | 2009 | 882 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2010 | 1756 | 0.020 |
Why?
|
| Physical Therapy Modalities | 1 | 2010 | 533 | 0.020 |
Why?
|
| Denmark | 1 | 2009 | 777 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 2015 | 9611 | 0.020 |
Why?
|
| Cystic Fibrosis | 1 | 2015 | 1285 | 0.020 |
Why?
|
| Motor Activity | 1 | 2016 | 2711 | 0.020 |
Why?
|
| Folic Acid | 1 | 2013 | 1337 | 0.020 |
Why?
|
| Base Sequence | 1 | 2017 | 12415 | 0.020 |
Why?
|
| Commerce | 1 | 2011 | 614 | 0.020 |
Why?
|
| Macular Degeneration | 1 | 2013 | 1015 | 0.020 |
Why?
|
| Heart | 1 | 2019 | 4425 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 1996 | 1659 | 0.020 |
Why?
|
| Stroke | 1 | 2008 | 9741 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2017 | 13411 | 0.020 |
Why?
|
| Computer Simulation | 2 | 2016 | 6259 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2018 | 15831 | 0.020 |
Why?
|
| Focus Groups | 1 | 2012 | 1459 | 0.020 |
Why?
|
| Selection Bias | 1 | 2007 | 359 | 0.020 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2007 | 361 | 0.020 |
Why?
|
| Celiac Disease | 1 | 2013 | 821 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2019 | 5343 | 0.010 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2008 | 371 | 0.010 |
Why?
|
| Internal-External Control | 1 | 2006 | 348 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2016 | 2085 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2017 | 4924 | 0.010 |
Why?
|
| Israel | 1 | 2006 | 726 | 0.010 |
Why?
|
| Visual Cortex | 1 | 2012 | 1081 | 0.010 |
Why?
|
| Introns | 1 | 2007 | 966 | 0.010 |
Why?
|
| Acetaminophen | 1 | 2008 | 549 | 0.010 |
Why?
|
| Vesicular Transport Proteins | 1 | 2007 | 376 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 4400 | 0.010 |
Why?
|
| Endosomes | 1 | 2007 | 521 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 2010 | 12985 | 0.010 |
Why?
|
| History, 21st Century | 1 | 2010 | 1574 | 0.010 |
Why?
|
| ROC Curve | 1 | 2012 | 3620 | 0.010 |
Why?
|
| Longevity | 1 | 2011 | 1083 | 0.010 |
Why?
|
| Angina Pectoris | 1 | 2007 | 956 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2015 | 3609 | 0.010 |
Why?
|
| Observer Variation | 1 | 2010 | 2614 | 0.010 |
Why?
|
| International Cooperation | 1 | 2010 | 1434 | 0.010 |
Why?
|
| Pyridines | 1 | 2015 | 2888 | 0.010 |
Why?
|
| Corpus Callosum | 1 | 1988 | 751 | 0.010 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2013 | 1899 | 0.010 |
Why?
|
| Brain Infarction | 1 | 2005 | 284 | 0.010 |
Why?
|
| Autistic Disorder | 1 | 2013 | 1238 | 0.010 |
Why?
|
| Health Surveys | 1 | 2013 | 4055 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2019 | 8533 | 0.010 |
Why?
|
| Models, Biological | 2 | 2010 | 9461 | 0.010 |
Why?
|
| Hyperlipidemias | 1 | 2008 | 771 | 0.010 |
Why?
|
| Walking | 1 | 2010 | 1201 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 2846 | 0.010 |
Why?
|
| RNA | 1 | 2012 | 2715 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2007 | 1966 | 0.010 |
Why?
|
| Anxiety Disorders | 1 | 2013 | 2744 | 0.010 |
Why?
|
| Atrial Fibrillation | 2 | 2013 | 5182 | 0.010 |
Why?
|
| Radiography | 1 | 2013 | 6968 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 4904 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2006 | 1742 | 0.010 |
Why?
|
| Social Support | 1 | 2011 | 2191 | 0.010 |
Why?
|
| Emergency Service, Hospital | 2 | 2012 | 7871 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2010 | 2028 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 9525 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2012 | 2678 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2011 | 2116 | 0.010 |
Why?
|
| Occupational Diseases | 1 | 2009 | 1456 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2007 | 2659 | 0.010 |
Why?
|
| Crohn Disease | 1 | 2013 | 2286 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2011 | 5306 | 0.010 |
Why?
|
| Aphasia, Broca | 1 | 1980 | 52 | 0.010 |
Why?
|
| Curriculum | 1 | 2014 | 3783 | 0.010 |
Why?
|
| Pediatrics | 1 | 2015 | 3614 | 0.010 |
Why?
|
| Disability Evaluation | 1 | 2007 | 1827 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2010 | 2704 | 0.010 |
Why?
|
| Causality | 1 | 2006 | 1252 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2017 | 4880 | 0.010 |
Why?
|
| Western World | 1 | 1999 | 26 | 0.010 |
Why?
|
| Ginkgo biloba | 1 | 1999 | 26 | 0.010 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2005 | 951 | 0.010 |
Why?
|
| Health Promotion | 1 | 2011 | 2209 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 6066 | 0.010 |
Why?
|
| Self Report | 1 | 2011 | 3771 | 0.010 |
Why?
|
| Indans | 1 | 1999 | 92 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 1990 | 2971 | 0.010 |
Why?
|
| Plants, Medicinal | 1 | 1999 | 166 | 0.010 |
Why?
|
| Apoptosis | 1 | 2015 | 9513 | 0.010 |
Why?
|
| Aphasia | 1 | 1980 | 193 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2014 | 4858 | 0.010 |
Why?
|
| Mortality | 1 | 2009 | 2910 | 0.010 |
Why?
|
| Asia | 1 | 1999 | 629 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 17088 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2007 | 2815 | 0.010 |
Why?
|
| Fear | 1 | 2006 | 1496 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2010 | 3359 | 0.010 |
Why?
|
| Poverty | 1 | 2009 | 2714 | 0.010 |
Why?
|
| Phytotherapy | 1 | 1999 | 297 | 0.010 |
Why?
|
| Serial Learning | 1 | 1996 | 41 | 0.010 |
Why?
|
| Tacrine | 1 | 1996 | 4 | 0.010 |
Why?
|
| Aspirin | 1 | 2008 | 3135 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2003 | 1791 | 0.010 |
Why?
|
| Complementary Therapies | 1 | 1999 | 486 | 0.010 |
Why?
|
| Internship and Residency | 1 | 1995 | 5943 | 0.010 |
Why?
|
| Ophthalmic Solutions | 1 | 1996 | 312 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 8926 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2010 | 3792 | 0.010 |
Why?
|
| Verbal Learning | 1 | 1996 | 459 | 0.010 |
Why?
|
| Survival Rate | 1 | 2007 | 12825 | 0.010 |
Why?
|
| Cell Line | 1 | 2007 | 15563 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 11920 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2008 | 65273 | 0.010 |
Why?
|
| South Australia | 1 | 1990 | 27 | 0.010 |
Why?
|
| Macrophages | 1 | 2005 | 5783 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2003 | 4045 | 0.010 |
Why?
|
| Animals | 2 | 2019 | 168930 | 0.010 |
Why?
|
| Twins | 1 | 1990 | 341 | 0.000 |
Why?
|
| Evaluation Studies as Topic | 1 | 1990 | 1622 | 0.000 |
Why?
|
| Hypertension | 1 | 2007 | 8616 | 0.000 |
Why?
|
| Pregnancy Trimester, Third | 1 | 1990 | 587 | 0.000 |
Why?
|
| Infant, Small for Gestational Age | 1 | 1990 | 468 | 0.000 |
Why?
|
| Speech Disorders | 1 | 1980 | 178 | 0.000 |
Why?
|
| Cerebral Infarction | 1 | 1980 | 968 | 0.000 |
Why?
|
| Functional Laterality | 1 | 1980 | 2243 | 0.000 |
Why?
|